Table of Contents Table of Contents
Previous Page  17 / 34 Next Page
Information
Show Menu
Previous Page 17 / 34 Next Page
Page Background

Treatment options in 2

nd

-3

rd

line

AXITINIB

NIVOLUMAB

CABOZANTINIB

LENVATINIB +

EVEROLIMUS

Motzer R et al Lancet Oncol 2016

1 … 12 13 14 15 16 17 18 19 20 21 22 23 … 34  FlippingBook